An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
100estimated
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-23 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Haemophilia A
Intervention
- Drug: Esperoct — also filed as Turoctocog alfa pegol (N8-GP)
Primary outcome
what the primary-completion date above is the date OFChange in haemophilia joint health score (HJHS)
measured From date of switch to end of study (up to 24 months)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed